Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYC2LE)

Drug Name

Disufenton Drug Info

Synonyms

168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726

Indication

Disease Entry	ICD 11	Status	REF
Recurrent glioblastoma	2A00.00	Phase 2	[1]

Cross-matching ID

PubChem CID: 151179
CAS Number: CAS 168021-77-0
TTD Drug ID: DMYC2LE

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular sulfatase Sulf-2 (SULF2)	TTLQTHB	SULF2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04388475) Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma. U.S. National Institutes of Health.
2	The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36.